FDA Advises on Pediatric Drug Development for Inflammatory Bowel Disease, Partial Onset Seizures

The FDA has issued new recommendations on pediatric drug trials, issuing a draft guidance on inflammatory bowel disease (IBD) drug development and a final guidance on extrapolating partial onset seizure (POS) drug efficacy from adults to patients one month and up.
Source: Drug Industry Daily